{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:21:09Z","timestamp":1791652869627,"version":"4.3.4"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Radiol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00256-019-03290-1","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T09:03:05Z","timestamp":1565254985000},"page":"199-219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4437-5237","authenticated-orcid":false,"given":"Shivani","family":"Ahlawat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishri O.","family":"Blakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Langmead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan J.","family":"Belzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,8]]},"reference":[{"key":"3290_CR1","doi-asserted-by":"crossref","unstructured":"National Institutes of Health consensus development conference. Neurofibromatosis. Conference statement. Arch Neurol. 1988;45(05):575\u20138.","DOI":"10.1001\/archneur.1988.00520290115023"},{"issue":"01","key":"3290_CR2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/0003-4819-113-1-39","volume":"113","author":"JJ Mulvihill","year":"1990","unstructured":"Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med. 1990;113(01):39\u201352.","journal-title":"Ann Intern Med"},{"issue":"11","key":"3290_CR3","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1212\/01.WNL.0000035638.74084.F4","volume":"59","author":"ME Baser","year":"2002","unstructured":"Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology. 2002;59(11):1759\u201365.","journal-title":"Neurology"},{"issue":"3","key":"3290_CR4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ajmg.a.35760","volume":"161A","author":"SR Plotkin","year":"2013","unstructured":"Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, et al. Update from the 2011 International Schwannomatosis Workshop: from genetics to diagnostic criteria. Am J Med Genet A. 2013;161A(3):405\u201316.","journal-title":"Am J Med Genet A"},{"key":"3290_CR5","doi-asserted-by":"crossref","unstructured":"Evans DG, King AT, Bowers NL, Tobi S, Wallace AJ, Perry M, et al. Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. Genet Med. 2018.","DOI":"10.1038\/s41436-018-0384-y"},{"issue":"1","key":"3290_CR6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1212\/WNL.0000000000003418","volume":"88","author":"MJ Smith","year":"2017","unstructured":"Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ, King AT, et al. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology. 2017;88(1):87\u201392.","journal-title":"Neurology"},{"issue":"1","key":"3290_CR7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ajmg.a.34376","volume":"158A","author":"MJ Smith","year":"2012","unstructured":"Smith MJ, Kulkarni A, Rustad C, Bowers NL, Wallace AJ, Holder SE, et al. Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis. Am J Med Genet. 2012;158A(1):215\u20139.","journal-title":"Am J Med Genet"},{"issue":"7","key":"3290_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/gim.2018.28","volume":"20","author":"DR Stewart","year":"2018","unstructured":"Stewart DR, Korf BR, Nathanson KL, Stevenson DA, Yohay K. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018;20(7):671\u201382. \nhttps:\/\/doi.org\/10.1038\/gim.2018.28\n\n.","journal-title":"Genet Med"},{"issue":"5","key":"3290_CR9","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1148\/radiographics.19.5.g99se101253","volume":"19","author":"MD Murphey","year":"1999","unstructured":"Murphey MD, Smith WS, Smith SE, Kransdorf MJ, Temple HT. From the archives of the AFIP. Imaging of musculoskeletal neurogenic tumors: radiologic-pathologic correlation. Radiographics. 1999;19(5):1253\u201380.","journal-title":"Radiographics"},{"issue":"2","key":"3290_CR10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s002470050082","volume":"27","author":"R Bhargava","year":"1997","unstructured":"Bhargava R, Parham DM, Lasater OE, Chari RS, Chen G, Fletcher BD. MR imaging differentiation of benign and malignant peripheral nerve sheath tumors: use of the target sign. Pediatr Radiol. 1997;27(2):124\u20139.","journal-title":"Pediatr Radiol"},{"issue":"6","key":"3290_CR11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00381-017-3340-2","volume":"33","author":"R Caltabiano","year":"2017","unstructured":"Caltabiano R, Magro G, Polizzi A, Pratic\u00f2 AD, Ortensi A, D\u2019Orazi V, et al. A mosaic pattern of INI1\/SMARCB1 protein expression distinguishes schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas. Childs Nerv Syst. 2017;33(6):933\u201340.","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"3290_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/s-0038-1627471","volume":"38","author":"SR Plotkin","year":"2018","unstructured":"Plotkin SR, Wick A. Neurofibromatosis and schwannomatosis. Semin Neurol. 2018;38(1):73\u201385. \nhttps:\/\/doi.org\/10.1055\/s-0038-1627471\n\n.","journal-title":"Semin Neurol"},{"issue":"7 Suppl 1","key":"3290_CR13","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1212\/WNL.0000000000002929","volume":"87","author":"S Ahlawat","year":"2016","unstructured":"Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, et al. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. Neurology. 2016;87(7 Suppl 1):S31\u20139.","journal-title":"Neurology."},{"issue":"6","key":"3290_CR14","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/ajmg.a.36466","volume":"164A","author":"VL Merker","year":"2014","unstructured":"Merker VL, Bredella MA, Cai W, Kassarjian A, Harris GJ, Muzikansky A, et al. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A. 2014;164A(6):1431\u20137.","journal-title":"Am J Med Genet A"},{"key":"3290_CR15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035711","volume":"7","author":"SR Plotkin","year":"2012","unstructured":"Plotkin SR, Bredella MA, Cai W, et al. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One. 2012;7:e35711.","journal-title":"PLoS One"},{"key":"3290_CR16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/gcc.21931","volume":"51","author":"L Kluwe","year":"2012","unstructured":"Kluwe L, Nguyen R, Vogt J, et al. Internal tumor burden in neurofibromatosis type I patients with large NF1 deletions. Genes Chromosom Cancer. 2012;51:447\u201351.","journal-title":"Genes Chromosom Cancer"},{"key":"3290_CR17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jpeds.2011.04.008","volume":"159","author":"R Nguyen","year":"2011","unstructured":"Nguyen R, Kluwe L, Fuensterer C, Kentsch M, Friedrich RE, Mautner VF. Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. J Pediatr. 2011;159:652\u2013655.e2.","journal-title":"J Pediatr"},{"key":"3290_CR18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1148\/radiol.2503080700","volume":"250","author":"W Cai","year":"2009","unstructured":"Cai W, Kassarjian A, Bredella MA, et al. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology. 2009;250:665\u201373.","journal-title":"Radiology"},{"key":"3290_CR19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejrad.2008.10.024","volume":"69","author":"SF Van Meerbeeck","year":"2009","unstructured":"Van Meerbeeck SF, Verstraete KL, Janssens S, Mortier G. Whole-body MR imaging in neurofibromatosis type 1. Eur J Radiol. 2009;69:236\u201342.","journal-title":"Eur J Radiol"},{"key":"3290_CR20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00256-011-1333-x","volume":"41","author":"JL Jaremko","year":"2012","unstructured":"Jaremko JL, MacMahon PJ, Torriani M, et al. Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis. Skelet Radiol. 2012;41:917\u201323.","journal-title":"Skelet Radiol"},{"issue":"4","key":"3290_CR21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1215\/15228517-2008-011","volume":"10","author":"VF Mautner","year":"2008","unstructured":"Mautner VF, Asuagbor FA, Dombi E, F\u00fcnsterer C, Kluwe L, Wenzel R, et al. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro-Oncology. 2008;10(4):593\u20138.","journal-title":"Neuro-Oncology"},{"key":"3290_CR22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-013-1293-1","volume":"116","author":"R Nguyen","year":"2014","unstructured":"Nguyen R, Jett K, Harris GJ, et al. Benign whole-body tumor volume is a risk factor malignant peripheral nerve sheath tumors in neurofibromatosis type 1. J Neuro-Oncol. 2014;116:307\u201313.","journal-title":"J Neuro-Oncol"},{"key":"3290_CR23","doi-asserted-by":"crossref","first-page":"627932","DOI":"10.5402\/2013\/627932","volume":"2013","author":"LM Fayad","year":"2013","unstructured":"Fayad LM, Blakeley J, Plotkin S, Widemann B, Jacobs MA. Whole body MRI at 3T with quantitative diffusion-weighted imaging and contrast-enhanced sequences for the characterization of peripheral lesions in patients with neurofibromatosis type 2 and schwannomatosis. ISRN Radiol. 2013;2013:627932.","journal-title":"ISRN Radiol"},{"issue":"4","key":"3290_CR24","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/jmri.25236","volume":"44","author":"S Ahlawat","year":"2016","unstructured":"Ahlawat S, Baig A, Blakeley JO, Jacobs MA, Fayad LM. Multiparametric whole-body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis. J Magn Reson Imaging. 2016;44(4):794\u2013803.","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"3290_CR25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-009-9867-7","volume":"93","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Halpin C, Blakeley JO, Slattery WH 3rd, Welling DB, Chang SM, et al. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neuro-Oncol. 2009;93(1):61\u201377.","journal-title":"J Neuro-Oncol"},{"issue":"2","key":"3290_CR26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/jmri.24994","volume":"43","author":"S Ahlawat","year":"2016","unstructured":"Ahlawat S, Khandheria P, Del Grande F, Morelli J, Subhawong TK, Demehri S, et al. Interobserver variability of selective region-of-interest measurement protocols for quantitative diffusion-weighted imaging in soft tissue masses: comparison with whole tumor volume measurements. J Magn Reson Imaging. 2016;43(2):446\u201354.","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"3290_CR27","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1148\/radiol.2015142463","volume":"278","author":"T Soldatos","year":"2016","unstructured":"Soldatos T, Ahlawat S, Montgomery E, Chalian M, Jacobs MA, Fayad LM. Multiparametric assessment of treatment response in high-grade soft-tissue sarcomas with anatomic and functional MR imaging sequences. Radiology. 2016;278(3):831\u201340.","journal-title":"Radiology"},{"key":"3290_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejrad.2018.03.018","volume":"102","author":"S Ahlawat","year":"2018","unstructured":"Ahlawat S, Fayad LM. Imaging cellularity in benign and malignant peripheral nerve sheath tumors: utility of the \u201ctarget sign\u201d by diffusion-weighted imaging. Eur J Radiol. 2018;102:195\u2013201. \nhttps:\/\/doi.org\/10.1016\/j.ejrad.2018.03.018\n\n.","journal-title":"Eur J Radiol"},{"issue":"8","key":"3290_CR29","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3174\/ajnr.A3910","volume":"35","author":"S Demehri","year":"2014","unstructured":"Demehri S, Belzberg A, Blakeley J, Fayad LM. Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience. AJNR Am J Neuroradiol. 2014;35(8):1615\u201320.","journal-title":"AJNR Am J Neuroradiol"},{"key":"3290_CR30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1148\/radiology.168.2.3393671","volume":"168","author":"D Le Bihan","year":"1988","unstructured":"Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology. 1988;168:497\u2013505.","journal-title":"Radiology"},{"issue":"2","key":"3290_CR31","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1148\/radiol.12111740","volume":"265","author":"LM Fayad","year":"2012","unstructured":"Fayad LM, Jacobs MA, Wang X, Carrino JA, Bluemke DA. Musculoskeletal tumors: how to use anatomic, functional, and metabolic MR techniques. Radiology. 2012;265(2):340\u201356.","journal-title":"Radiology"},{"issue":"5","key":"3290_CR32","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1148\/rg.345140190","volume":"34","author":"TK Subhawong","year":"2014","unstructured":"Subhawong TK, Jacobs MA, Fayad LM. Diffusion-weighted MR imaging for characterizing musculoskeletal lesions. Radiographics. 2014;34(5):1163\u201377.","journal-title":"Radiographics"},{"issue":"12","key":"3290_CR33","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","volume":"20","author":"AM Gross","year":"2018","unstructured":"Gross AM, Singh G, Akshintala S, Baldwin A, Dombi E, Ukwuani S, et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro-Oncology. 2018;20(12):1643\u201351.","journal-title":"Neuro-Oncology"},{"issue":"4","key":"3290_CR34","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/neuonc\/nou235","volume":"17","author":"B Weiss","year":"2015","unstructured":"Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, et al. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis clinical trials consortium phase II study. Neuro-Oncology. 2015;17(4):596\u2013603. \nhttps:\/\/doi.org\/10.1093\/neuonc\/nou235\n\n Erratum in: Neuro Oncol. 2015 Jun;17(6):905.","journal-title":"Neuro-Oncology"},{"issue":"26","key":"3290_CR35","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"JB Belasco","year":"2016","unstructured":"Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375(26):2550\u201360. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1605943\n\n.","journal-title":"N Engl J Med"},{"issue":"4908","key":"3290_CR36","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1126\/science.2543076","volume":"244","author":"JW Fountain","year":"1989","unstructured":"Fountain JW, Wallace MR, Bruce MA, Seizinger BR, Menon AG, Gusella JF, et al. Physical mapping of a translocation breakpoint in neurofibromatosis. Science. 1989;244(4908):1085\u20137.","journal-title":"Science."},{"issue":"2","key":"3290_CR37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family geneticregister service. Am J Med Genet A. 2010;152A(2):327.","journal-title":"Am J Med Genet A"},{"issue":"3","key":"3290_CR38","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00197259","volume":"88","author":"K Stephens","year":"1992","unstructured":"Stephens K, Kayes L, Riccardi VM, Rising M, Sybert VP, Pagon RA. Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes. Hum Genet. 1992;88(3):279\u201382.","journal-title":"Hum Genet"},{"issue":"11","key":"3290_CR39","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1212\/WNL.56.11.1433","volume":"56","author":"M Ruggieri","year":"2001","unstructured":"Ruggieri M. Huson SM the clinical and diagnostic implications of mosaicism in the neurofibromatoses. Neurology. 2001;56(11):1433.","journal-title":"Neurology."},{"issue":"1","key":"3290_CR40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/bjc.2012.535","volume":"108","author":"OO Seminog","year":"2013","unstructured":"Seminog OO, Goldacre MJ. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. Br J Cancer. 2013;108(1):193\u20138.","journal-title":"Br J Cancer"},{"issue":"6","key":"3290_CR41","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1186\/1479-7364-5-6-623","volume":"5","author":"S Laycock-van Spyk","year":"2011","unstructured":"Laycock-van Spyk S, Thomas N, Cooper DN, Upadhyaya M. Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics. 2011;5(6):623\u201390.","journal-title":"Hum Genomics"},{"issue":"11","key":"3290_CR42","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1182\/blood.V88.11.4314.bloodjournal88114314","volume":"88","author":"DK Miles","year":"1996","unstructured":"Miles DK, Freedman MH, Stephens K, Pallavicini M, Sievers EL, Weaver M, et al. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders. Blood. 1996;88(11):4314\u201320.","journal-title":"Blood"},{"issue":"04","key":"3290_CR43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jmedgenet-2011-100562","volume":"49","author":"A Wilding","year":"2012","unstructured":"Wilding A, Ingham SL, Lalloo F, et al. Life expectancy in hereditary cancer predisposing diseases: an observational study. J Med Genet. 2012;49(04):264\u20139.","journal-title":"J Med Genet"},{"issue":"17","key":"3290_CR44","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","volume":"34","author":"E Uusitalo","year":"2016","unstructured":"Uusitalo E, Rantanen M, Kallionp\u00e4\u00e4 RA, P\u00f6yh\u00f6nen M, Lepp\u00e4virta J, Yl\u00e4-Outinen H, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016;34(17):1978\u201386.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3290_CR45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DG Evans","year":"2002","unstructured":"Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39(5):311\u20134.","journal-title":"J Med Genet"},{"issue":"16","key":"3290_CR46","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJM198604173141603","volume":"314","author":"SA S\u00f8rensen","year":"1986","unstructured":"S\u00f8rensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med. 1986;314(16):1010\u20135.","journal-title":"N Engl J Med"},{"issue":"2","key":"3290_CR47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bjc.6603227","volume":"95","author":"L Walker","year":"2006","unstructured":"Walker L, Thompson D, Easton D, Ponder B, Ponder M, Frayling I, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer. 2006;95(2):233\u20138.","journal-title":"Br J Cancer"},{"issue":"3","key":"3290_CR48","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-4851-6","volume":"171","author":"Yoon-Sim Yap","year":"2018","unstructured":"Yap YS, Munusamy P, Lim C, Chan CHT, Prawira A, Loke SY, et al. Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype. Breast Cancer Res Treat. 2018. \nhttps:\/\/doi.org\/10.1007\/s10549-018-4851-6\n\n.","journal-title":"Breast Cancer Research and Treatment"},{"key":"3290_CR49","doi-asserted-by":"publisher","unstructured":"Wang X, Teer JK, Tousignant RN, Levin AM, Boulware D, Chitale DA, et al. Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer. Genes Chromosom Cancer. 2018;57(1):19\u201327. \nhttps:\/\/doi.org\/10.1002\/gcc.22503.E\n\n.","DOI":"10.1002\/gcc.22503.E"},{"key":"3290_CR50","first-page":"531","volume":"9","author":"SJ Howell","year":"2017","unstructured":"Howell SJ, Hockenhull K, Salih Z, Evans DG. Increased risk of breast cancer in neurofibromatosis type 1: current insights. Breast Cancer (Dove Med Press). 2017;9:531\u20136.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"9","key":"3290_CR51","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/bjc.2015.78","volume":"112","author":"OO Seminog","year":"2015","unstructured":"Seminog OO, Goldacre MJ. Age-specific risk of breast cancer in women with neurofibromatosis type 1. Br J Cancer. 2015;112(9):1546\u20138. \nhttps:\/\/doi.org\/10.1038\/bjc.2015.78\n\n.","journal-title":"Br J Cancer"},{"key":"3290_CR52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1172-6-18","volume":"6","author":"TA Duong","year":"2011","unstructured":"Duong TA, Sbidian E, Valeyrie-Allanore L, et al. Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France. Orphanet J Rare Dis. 2011;6:18.","journal-title":"Orphanet J Rare Dis."},{"issue":"2","key":"3290_CR53","first-page":"139","volume":"121","author":"M Poyhonen","year":"1997","unstructured":"Poyhonen M, Niemela S, Herva R. Risk of malignancy and death in neurofibromatosis. Arch Pathol Lab Med. 1997;121(2):139\u201343.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"3290_CR54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jaad.2014.01.913","volume":"71","author":"MG Kumar","year":"2014","unstructured":"Kumar MG, Emnett RJ, Bayliss SJ, Gutmann DH. Glomus tumors in individuals with neurofibromatosis type 1. J Am Acad Dermatol. 2014;71(1):44\u20138. \nhttps:\/\/doi.org\/10.1016\/j.jaad.2014.01.913\n\n.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"3290_CR55","doi-asserted-by":"publisher","first-page":"792","DOI":"10.4158\/EP13417","volume":"20","author":"MC Shinall","year":"2014","unstructured":"Shinall MC, Sol\u00f3rzano CC. Pheochromocytoma in Neurofibromatosis type 1: when should it be suspected? Endocr Pract. 2014;20(8):792\u20136. \nhttps:\/\/doi.org\/10.4158\/EP13417\n\n.","journal-title":"Endocr Pract"},{"key":"3290_CR56","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1002\/ajmg.a.35585","volume":"158a","author":"DG Evans","year":"2012","unstructured":"Evans DG. Are we ready for targeted early breast cancer detection strategies in women with NF1 aged 30-49 years? Am J Med Genet A. 2012;158a:3054\u20135.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"3290_CR57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","volume":"15","author":"MB Daly","year":"2017","unstructured":"Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, et al. NCCN guidelines insights: genetic\/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Cancer Netw. 2017;15(1):9\u201320.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"3290_CR58","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00467-015-3191-6","volume":"31","author":"T Dubov","year":"2016","unstructured":"Dubov T, Toledano-Alhadef H, Chernin G, Constantini S, Cleper R, Ben-Shachar S. High prevalence of elevated blood pressure among children with neurofibromatosis type 1. Pediatr Nephrol. 2016;31(1):131\u20136. \nhttps:\/\/doi.org\/10.1007\/s00467-015-3191-6\n\n.","journal-title":"Pediatr Nephrol"},{"key":"3290_CR59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2015.12.015","volume":"56","author":"T Valentin","year":"2016","unstructured":"Valentin T, Le Cesne A, Ray-Coquard I, et al. Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer. 2016;56:77\u201384.","journal-title":"Eur J Cancer"},{"issue":"3","key":"3290_CR60","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000458525","volume":"87","author":"I Sani","year":"2017","unstructured":"Sani I, Albanese A. Endocrine long-term follow-up of children with neurofibromatosis type 1 and optic pathway glioma. Horm Res Paediatr. 2017;87(3):179\u201388. \nhttps:\/\/doi.org\/10.1159\/000458525\n\n.","journal-title":"Horm Res Paediatr"},{"key":"3290_CR61","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00234-012-1010-3","volume":"54","author":"S Gaudino","year":"2012","unstructured":"Gaudino S, Quaglio F, Schiarelli C, Martucci M, Tartaglione T, Gualano MR, et al. Spontaneous modifications of contrast enhancement in childhood non-cerebellar pilocytic astrocytomas. Neuroradiology. 2012;54:989\u201395.","journal-title":"Neuroradiology"},{"issue":"Suppl 1","key":"3290_CR62","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1097\/WNO.0000000000000550","volume":"37","author":"PMK de Blank","year":"2017","unstructured":"de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, et al. Optic pathway gliomas in Neurofibromatosis type 1: an update: surveillance, treatment indications, and biomarkers of vision. J Neuroophthalmol. 2017;37(Suppl 1):S23\u201332. \nhttps:\/\/doi.org\/10.1097\/WNO.0000000000000550\n\n Review.","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"3290_CR63","doi-asserted-by":"publisher","first-page":"e26733","DOI":"10.1002\/pbc.26733","volume":"65","author":"Amedeo A. Azizi","year":"2017","unstructured":"Azizi AA, Slavc I, Theisen BE, Rausch I, Weber M, Happak W, et al. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [(18) F]FDG-PET imaging. Is it of value in asymptomatic patients? Pediatr Blood Cancer. 2018;65(1). \nhttps:\/\/doi.org\/10.1002\/pbc.26733\n\n.","journal-title":"Pediatric Blood & Cancer"},{"issue":"1","key":"3290_CR64","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/pbc.24212","volume":"60","author":"H Meany","year":"2013","unstructured":"Meany H, Dombi E, Reynolds J, Whatley M, Kurwa A, Tsokos M, et al. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). Pediatr Blood Cancer. 2013;60(1):59\u201364.","journal-title":"Pediatr Blood Cancer"},{"key":"3290_CR65","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.wneu.2017.09.066","volume":"108","author":"L Zhang","year":"2017","unstructured":"Zhang L, Dessouky R, Xi Y, Chhabra A, Le LQ. Clinical value of multiparametric whole-body magnetic resonance imaging over whole-spine magnetic resonance imaging in patients with neurofibromatosis type I. World Neurosurg. 2017;108:729\u201337.","journal-title":"World Neurosurg"},{"issue":"6","key":"3290_CR66","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/neuonc\/noy013","volume":"20","author":"CS Higham","year":"2018","unstructured":"Higham CS, Dombi E, Rogiers A, Bhaumik S, Pans S, Connor SEJ, et al. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1-associated malignant peripheral nerve sheath tumors. Neuro-Oncology. 2018;20(6):818\u201325.","journal-title":"Neuro-Oncology"},{"issue":"1","key":"3290_CR67","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1097\/RLU.0b013e318266ce84","volume":"38","author":"T Derlin","year":"2013","unstructured":"Derlin T, Tornquist K, M\u00fcnster S, Apostolova I, Hagel C, Friedrich RE, et al. Comparative effectiveness of 18F-FDG PET\/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med. 2013;38(1):e19\u201325.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"3290_CR68","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2967\/jnumed.114.142372","volume":"56","author":"A Chirindel","year":"2015","unstructured":"Chirindel A, Chaudhry M, Blakeley JO, Wahl R. 18F-FDG PET\/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization. J Nucl Med. 2015;56(3):379\u201385. \nhttps:\/\/doi.org\/10.2967\/jnumed.114.142372\n\n.","journal-title":"J Nucl Med"},{"key":"3290_CR69","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jnnp.68.3.353","volume":"68","author":"RE Ferner","year":"2000","unstructured":"Ferner RE, Lucas JD, O\u2019Doherty MJ, et al. Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDGPET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000;68:353\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3290_CR70","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0748-7983(03)00055-6","volume":"29","author":"S Cardona","year":"2003","unstructured":"Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, Mechtersheimer G, et al. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol. 2003;29:536\u201341.","journal-title":"Eur J Surg Oncol"},{"key":"3290_CR71","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2214\/AJR.07.2060","volume":"189","author":"MA Bredella","year":"2007","unstructured":"Bredella MA, Torriani M, Hornicek F, Ouellette HA, Palmer WE, Williams Z, et al. Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol. 2007;189:928\u201335.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"3290_CR72","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/annonc\/mdm450","volume":"19","author":"RE Ferner","year":"2008","unstructured":"Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, et al. [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008;19(2):390\u20134.","journal-title":"Ann Oncol"},{"issue":"5","key":"3290_CR73","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00259-008-1038-0","volume":"36","author":"VS Warbey","year":"2009","unstructured":"Warbey VS, Ferner RE, Dunn JT, Calonje E, O\u2019Doherty MJ. [18F]FDG PET\/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging. 2009;36(5):751\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3290_CR74","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00330-013-3020-x","volume":"24","author":"J Salamon","year":"2014","unstructured":"Salamon J, Veldhoen S, Apostolova I, et al. 18F-FDG PET\/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1:tumour-to-liver ratio is superior to an SUVmax cut-off. Eur Radiol. 2014;24:405\u201312.","journal-title":"Eur Radiol"},{"key":"3290_CR75","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1097\/RLU.0b013e3182a757d3","volume":"39","author":"T Urban","year":"2014","unstructured":"Urban T, Lim R, Merker VL, et al. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion. Clin Nucl Med. 2014;39:e301\u20137.","journal-title":"Clin Nucl Med"},{"issue":"5","key":"3290_CR76","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3174\/ajnr.A3778","volume":"35","author":"LM Fayad","year":"2014","unstructured":"Fayad LM, Wang X, Blakeley JO, Durand DJ, Jacobs MA, Demehri S, et al. Characterization of peripheral nerve sheath tumors with 3T proton MR spectroscopy. AJNR Am J Neuroradiol. 2014;35(5):1035\u201341.","journal-title":"AJNR Am J Neuroradiol"},{"key":"3290_CR77","unstructured":"Friedman JM. Neurofibromatosis 1. 1998 Oct 2 [updated 2018 May 17]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, LJH B, Stephens K, Amemiya A, editors. GeneReviews\u00ae [Internet]. Seattle: University of Washington, Seattle; 1993-2018. Available from \nhttp:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1109\/PubMed\n\n."},{"issue":"9","key":"3290_CR78","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/GIM.0b013e3181ac9a27","volume":"11","author":"DG Evans","year":"2009","unstructured":"Evans DG. Neurofibromatosis 2 [bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med. 2009;11(9):599\u2013610.","journal-title":"Genet Med."},{"key":"3290_CR79","volume-title":"GeneReviews\u00ae [Internet]","author":"DG Evans","year":"1993","unstructured":"Evans DG. Neurofibromatosis 2. 1998 Oct 14 [updated 2018 mar 15]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, LJH B, Stephens K, Amemiya A, editors. GeneReviews\u00ae [Internet]. Seattle: University of Washington, Seattle; 1993-2018."},{"key":"3290_CR80","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/342716","volume":"71","author":"ME Baser","year":"2002","unstructured":"Baser ME, Friedman JM, Aeschilman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. 2002;71:715\u201323.","journal-title":"Am J Hum Genet"},{"key":"3290_CR81","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1148\/radiology.218.2.r01fe40434","volume":"218","author":"NJ Patronas","year":"2001","unstructured":"Patronas NJ, Courcoutsakis N, Bromley CM, Katzman GL, MacCollin M, Parry DM. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology. 2001;218:434\u201342.","journal-title":"Radiology"},{"key":"3290_CR82","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3171\/spi.2005.2.5.0574","volume":"2","author":"G Dow","year":"2005","unstructured":"Dow G, Biggs N, Evans G, Gillespie J, Ramsden RT, King A. Spinal tumors in neurofibromatosis type 2: is emerging knowledge of genotype predictive of natural history? J Neurosurg Spine. 2005;2:574\u20139.","journal-title":"J Neurosurg Spine"},{"issue":"10","key":"3290_CR83","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1634\/theoncologist.2012-0162","volume":"17","author":"VL Merker","year":"2012","unstructured":"Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist. 2012;17(10):1317\u201322.","journal-title":"Oncologist"},{"issue":"11","key":"3290_CR84","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1212\/01.WNL.0000163982.78900.AD","volume":"64","author":"M MacCollin","year":"2005","unstructured":"MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, et al. Diagnostic criteria for schwannomatosis. Neurology. 2005;64(11):1838\u201345.","journal-title":"Neurology"},{"issue":"6-7","key":"3290_CR85","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00439-018-1909-9","volume":"137","author":"Hildegard Kehrer-Sawatzki","year":"2018","unstructured":"Kehrer-Sawatzki H, Kluwe L, Friedrich RE, Summerer A, Sch\u00e4fer E, Wahll\u00e4nder U, et al. Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas. Hum Genet. 2018. \nhttps:\/\/doi.org\/10.1007\/s00439-018-1909-9\n\n.","journal-title":"Human Genetics"},{"key":"3290_CR86","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp-2018-318538","volume":"89","author":"DG Evans","year":"2018","unstructured":"Evans DG, Bowers NL, Tobi S, Hartley C, Wallace AJ, King AT, et al. Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry. 2018;89:1215\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3290_CR87","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jocn.2016.01.027","volume":"30","author":"B Lieber","year":"2016","unstructured":"Lieber B, Han B, Allen J, Fatterpekar G, Agarwal N, Kazemi N, et al. Utility of positron emission tomography in schwannomatosis. J Clin Neurosci. 2016;30:138\u201340. \nhttps:\/\/doi.org\/10.1016\/j.jocn.2016.01.027\n\n.","journal-title":"J Clin Neurosci"},{"issue":"4","key":"3290_CR88","first-page":"275","volume":"32","author":"V Beylergil","year":"2013","unstructured":"Beylergil V, Haque S, Carver A, Bilsky MH, Carrasquillo JA. Schwannomatosis\/ neurofibromatosis type 2 associated multiple schwannomas visualized on FDG-PET\/CT. Rev Esp Med Nucl Imagen Mol. 2013;32(4):275\u20136.","journal-title":"Rev Esp Med Nucl Imagen Mol"}],"container-title":["Skeletal Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-019-03290-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00256-019-03290-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-019-03290-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T19:10:37Z","timestamp":1596741037000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00256-019-03290-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,8]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["3290"],"URL":"https:\/\/doi.org\/10.1007\/s00256-019-03290-1","relation":{},"ISSN":["0364-2348","1432-2161"],"issn-type":[{"value":"0364-2348","type":"print"},{"value":"1432-2161","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,8]]},"assertion":[{"value":"7 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}